Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by CureVac
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
July 05, 2022
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Tickers
CVAC
CureVac Announces Voting Results of General Meeting
June 22, 2022
From
CureVac
Via
AccessWire
Exposures
COVID-19
Tickers
CVAC
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
June 08, 2022
From
CureVac
Via
AccessWire
Tickers
CVAC
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
June 08, 2022
From
CureVac
Via
AccessWire
Tickers
CVAC
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
May 25, 2022
From
CureVac
Via
AccessWire
Tickers
CVAC
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
May 25, 2022
From
CureVac
Via
AccessWire
Exposures
COVID-19
Tickers
CVAC
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
April 28, 2022
From
CureVac
Via
AccessWire
Exposures
COVID-19
Tickers
CVAC
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
April 22, 2022
From
CureVac
Via
AccessWire
Tickers
CVAC
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
April 21, 2022
From
CureVac
Via
AccessWire
Exposures
COVID-19
Tickers
CVAC
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
April 11, 2022
From
CureVac
Via
AccessWire
Tickers
CVAC
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
March 30, 2022
From
CureVac
Via
AccessWire
Exposures
COVID-19
Tickers
CVAC
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
March 01, 2022
From
CureVac
Via
AccessWire
Exposures
COVID-19
Tickers
CVAC
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
February 10, 2022
From
CureVac
Via
AccessWire
Tickers
CVAC
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
January 17, 2022
From
CureVac
Via
AccessWire
Tickers
CVAC
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
November 19, 2021
From
CureVac
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Death
Intellectual Property
Tickers
CVAC
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
November 18, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
November 10, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
October 12, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac Streamlines European Network for mRNA Product Manufacturing
September 14, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
August 31, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
August 30, 2021
From
CureVac
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Death
Intellectual Property
Tickers
CVAC
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
August 16, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
August 16, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
June 30, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)
June 30, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac Announces Voting Results of General Meeting
June 25, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac Provides Supervisory Board Update
June 23, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
June 16, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac Appoints Klaus Edvardsen as Chief Development Officer
June 02, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
May 28, 2021
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
CVAC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.